Melodiol Global Health (ASX: ME1)

In early 2024, Melodiol Global Health (ASX: ME1), formerly known as Creso Pharma, faced scrutiny from the ASX, regarding corporate governance and financial disclosure which led to a major restructure and rebrand, but now the time has come to offload a major asset in an attempt for survival under its mounting debt obligations. Melodiol is

Recreational cannabis use has been a global topic for debate in the past few years but cannabinoids, a naturally occurring compound in cannabis, are now gaining momentum as a treatment for managing pain, inflammation and various mental health conditions like depression and PTSD. For the past several months, Melodiol Global Health’s (ASX: ME1) subsidiary, Health

Roots Sustainable Agricultural Technologies (ASX: ROO), who develops adaptable technologies to tackle critical problems faced by the agricultural and cannabis industry, entered a trading halt yesterday in preparation of a Capital Raise announced today.  For the Placement, Roots is committed to raising A$650,000 via a Placement which will be exclusively reserved for professional and sophisticated

To distance themselves from a plagued past, cannabis company Creso Pharma (ASX: CPH) has announced a complete business overhaul and rebranding to pave the way for growth and any future mergers and acquisitions (M&A) opportunities.  To kick off the revamp, Creso has appointed two new board directors to bolster its growth strategy to achieve global

With just four months of operating cash in the bank according to last month’s quarterly report, cannabis company Creso Pharma (ASX: CPH) are back in the headlines inking deals with the latest collaborative agreement to potentially enter the Australian body care market via Dr Pickles.  Key to the non-binding Heads of Agreement (HoA) signed is

There is an increasingly growing body of research globally into the use of psychedelic medicines to treat various health conditions. To date, this research has produced highly encouraging results and has promoted the development of an extensive psychedelic industry, which has kicked off in North America and the United Kingdom. The industry has now made

Putting behind them the drama of 2021 which resulted in their former Chairman’s offices being raided by Australian Federal Police, medicinal cannabis company Creso Pharma (ASX: CPH) has kicked off the new year with a bang, confirming their entry into the lucrative US market through the acquisition of Sierra Sage Herbs. Founded in 2008 by

According to the Australian Department of Health, half of us will experience some form of mental illness in our lifetime. Treatment is somewhat limited to prescription medications and psychotherapy. However, the current mental health crisis has seen researchers and practitioners alike wondering- is there a better way to approach these frighteningly common conditions? Enter psychedelics,

In a landmark decision that is tipped to normalise the use of medicinal cannabis, the United Nations has voted to remove cannabis from being a Schedule IV drug, sending the ASX cannabis sector upward in a regulatory move that will encourage individual nations to follow suit.  The UN drugs treaty was first introduced in 1961

Medicinal cannabis company Creso Pharma (ASX: CPH) is continuing to see strong international interest in their premium cannabis flowers with an order worth $930k placed from repeat Israeli client Univo Pharmaceuticals Ltd (TLV: UNVO).  The larger order for premium, cured and hand-trimmed dried medicinal cannabis flower follows on from an order for $820k of the